Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

PURPOSE: Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK),...

Descripción completa

Detalles Bibliográficos
Autores principales: Dennis, Mike, Davies, Michelle, Oliver, Stuart, D’Souza, Roy, Pike, Laura, Stockman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428523/
https://www.ncbi.nlm.nih.gov/pubmed/22864876
http://dx.doi.org/10.1007/s00280-012-1939-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428523/
https://www.ncbi.nlm.nih.gov/pubmed/22864876
http://dx.doi.org/10.1007/s00280-012-1939-2

Ejemplares similares